Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma’s innovative products mainly covered core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease).

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

  • 41,400 Million
    FY2023 Revenue
  • 2,011 Million
    FY2023 Net Profit after deducting extraordinary gain or loss attributable to owners of the parent
  • 5,937 Million
    FY2023 R&D Expenditure
  • 40,370
    Global Employees
  • Five-Star (Excellence)
    2022 Corporate Social Responsibility Report Rating
  • A
    MSCI ESG Rating
As of December 31, 2023
Unit: RMB million
  • Mission

    Better Health for Families Worldwide

  • Vision

    We are committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets

  • Values

    1. Care for Life
    2. Continuous Innovation
    3. Pursuit of Excellence
    4. Sustainable Partnership